Sodium-glucose cotransporter 2 inhibitors in heart failure: a meta-analysis of randomized clinical trials
Kumar K, Kheiri B, Simpson TF, et al.
Am J Med. 2020;S0002-9343(20)30361-2
Leggi
SGLT2 inhibitors and kidney outcomes in the real world
Smith SM
BMJ 2020;369:m1584
Leggi
Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study
Pasternak B, Wintzell V, Melbye M, et al.
BMJ 2020;369:m1186
Leggi
Risk factors and prevention strategies for diabetic ketoacidosis in people with established type 1 diabetes
Ehrmann D, Kulzer B, Roos T, et al.
Lancet Diabet Endocrinol. 2020;8(5):436-46
Leggi
Artificial intelligence in diabetes care
Ellahham S
Am J Med. Pub. online 20 April 2020
Leggi
Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial
Yabe D, Nakamura J, Kaneto H, et al.
Lancet Diabet Endocrinol. 2020;8(5):392-406
Leggi
Managing new-onset type 1 diabetes during the COVID-19 pandemic: challenges and opportunities
Garg SK, Rodbard D, Hirsch IB, Forlenza GP
Diabetes Technol Ther. Pub. online 17 April 2020
Leggi
Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials
Ghosh-Swaby OR, Goodman SG, Leiter LA, et al.
Lancet Diabet Endocrinol. 2020;8(5):418-35
Leggi
The association of ambient fine particulate matter exposure during pregnancy with blood glucose levels and gestational diabetes mellitus risk: a prospective cohort study in Wuhan, China
Ye B, Zhong C, Li Q, et al.
Am J Epidemiol. Pub. online 14 April 2020
Leggi
Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial
Yamada Y, Katagiri H, Hamamoto Y, et al.
Lancet Diabet Endocrinol. 2020;8(5):377-91
Leggi